Get started
Viracta Therapeutics, Inc.Viracta Therapeutics, Inc.Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VIRX chart


Full chart

VIRX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪8.51 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.1034 USD
Net income (FY)
‪−51.06 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪28.01 M‬
Beta (1Y)
−0.50

Employees


Employees (FY)
40
Change (1Y)
+8 +25.00%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.28 M‬ USD

About Viracta Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Mark A. Rothera
Website
viracta.com
Headquarters
Cardiff
Founded
1998
FIGI
BBG000BFG2V7
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VIRX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VIRX is 0.2100 USD — it has increased by 3.63% in the past 24 hours. Watch Viracta Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Viracta Therapeutics, Inc. stocks are traded under the ticker VIRX.
VIRX stock has risen by 26.63% compared to the previous week, the month change is a 42.95% rise, over the last year Viracta Therapeutics, Inc. has showed a −53.08% decrease.
We've gathered analysts' opinions on Viracta Therapeutics, Inc. future price: according to them, VIRX price has a max estimate of 3.50 USD and a min estimate of 3.00 USD. Watch VIRX chart and read a more detailed Viracta Therapeutics, Inc. stock forecast: see what analysts think of Viracta Therapeutics, Inc. and suggest that you do with its stocks.
VIRX reached its all-time high on Mar 30, 2006 with the price of 9,322.1352 USD, and its all-time low was 0.1315 USD and was reached on Nov 15, 2024. View more price dynamics on VIRX chart.
See other stocks reaching their highest and lowest prices.
VIRX stock is 22.57% volatile and has beta coefficient of −0.50. Track Viracta Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Viracta Therapeutics, Inc. there?
Today Viracta Therapeutics, Inc. has the market capitalization of ‪8.35 M‬, it has increased by 22.71% over the last week.
Yes, you can track Viracta Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Viracta Therapeutics, Inc. is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
VIRX earnings for the last quarter are −0.27 USD per share, whereas the estimation was −0.27 USD resulting in a −1.25% surprise. The estimated earnings for the next quarter are −0.16 USD per share. See more details about Viracta Therapeutics, Inc. earnings.
Viracta Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
VIRX net income for the last quarter is ‪−10.55 M‬ USD, while the quarter before that showed ‪−9.83 M‬ USD of net income which accounts for −7.36% change. Track more Viracta Therapeutics, Inc. financial stats to get the full picture.
No, VIRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 40.00 employees. See our rating of the largest employees — is Viracta Therapeutics, Inc. on this list?
Like other stocks, VIRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viracta Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Viracta Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Viracta Therapeutics, Inc. stock shows the sell signal. See more of Viracta Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.